Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 3Lymphoid 3Other hematologic neoplasm 2Genitourinary 2Gastrointestinal 2Breast 2Thoracic 1Sarcoma 1Head & Neck 1Gynecologic 1Dermatologic 1Classical hematology 1CNS 1

Conditions

Prostatic Neoplasms 1Carcinoma, Renal Cell 1

Interventions

Docetaxel 390pembrolizumab 325Prednisone 284Gemcitabine 273enzalutamide 254Radiotherapy 251Nivolumab 247Magnetic Resonance Spectroscopy 247Cisplatin 209Abiraterone Acetate 197Radiosurgery 184Leuprolide 182Sunitinib 169Carboplatin 161bicalutamide 148Goserelin 145Androgen Antagonists 142Specimen Handling 138Ipilimumab 128Paclitaxel 125Cyclophosphamide 116acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 110Bevacizumab 109Everolimus 107apalutamide 98cabozantinib 97abiraterone 97Sorafenib 97atezolizumab 96Radiation 89

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × ispinesib × Genitourinary × Clear all
NCT00354250 2013-06-05

Ispinesib in Treating Patients With Metastatic or Unresectable Kidney Cancer

National Cancer Institute (NCI)

Phase 2 Completed
60 enrolled
Genitourinary

Carcinoma, Renal Cell

NCT00096499 2013-01-25

SB-715992 in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Docetaxel or Paclitaxel

National Cancer Institute (NCI)

Phase 2 Completed
40 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡